1
|
Saiki M, Takemoto N, Nagata M, Matsumoto M, Amen Y, Wang D, Shimizu K. Analysis of Antioxidant and Antiallergic Active Components Extracted From the Edible Insect Oxya yezoensis. Nat Prod Commun 2021. [DOI: 10.1177/1934578x211023363] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
In recent years, entomophagy has attracted increased attention, as it was recommended as a potential source of food by the Food and Agriculture Organization of the United Nations. In Japan, Oxya yezoensisis one of the most widely eaten insect species, but studies of its functionality as a food are limited. In this study, we reported the optimal characterization of the total phenolic compounds in methanolic extract (OME) and different fractions of OME. Additionally, the antioxidant and antiallergic activities of the OME fractions were evaluated. The results showed that the ethyl acetate-soluble fraction of OME has potential antioxidant activity, whereas the n-hexane-soluble fraction showed the strongest inhibition of β-hexosaminidase, which is one of the key factors in allergic reactions. It was concluded that phenolic compounds might contribute to the antioxidant activity while unsaturated fatty acids contribute to the antiallergy activity.
Collapse
Affiliation(s)
- Masahiro Saiki
- Division of Systematic Forest and Forest Products Sciences, Department of Agro-Environmental Sciences, Graduate School of Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan
| | - Naomichi Takemoto
- Division of Systematic Forest and Forest Products Sciences, Department of Agro-Environmental Sciences, Graduate School of Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan
| | - Maki Nagata
- Division of Systematic Forest and Forest Products Sciences, Department of Agro-Environmental Sciences, Graduate School of Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan
| | - Masako Matsumoto
- Division of Systematic Forest and Forest Products Sciences, Department of Agro-Environmental Sciences, Graduate School of Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan
| | - Yhiya Amen
- Division of Systematic Forest and Forest Products Sciences, Department of Agro-Environmental Sciences, Graduate School of Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan
- Department of Pharmacognosy, Mansoura University, Mansoura, Egypt
| | - Dongmei Wang
- Division of Systematic Forest and Forest Products Sciences, Department of Agro-Environmental Sciences, Graduate School of Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan
| | - Kuniyoshi Shimizu
- Division of Systematic Forest and Forest Products Sciences, Department of Agro-Environmental Sciences, Graduate School of Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan
| |
Collapse
|
2
|
Mundi MS, Bonnes SL, Salonen BR, McMahon MM, Martindale R, Hurt RT. Clinical application of fish-oil intravenous lipid emulsion in adult home parenteral nutrition patients. Nutr Clin Pract 2020; 36:839-852. [PMID: 32970359 DOI: 10.1002/ncp.10581] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Accepted: 08/23/2020] [Indexed: 01/19/2023] Open
Abstract
BACKGROUND High-ω-6 polyunsaturated fatty acids (PUFAs) are noted to contribute to development of intestinal failure-associated liver disease (IFALD) in home parenteral nutrition (HPN). Fish oil (FO) has been added to latest generation of lipid injectable emulsion (ILE) to increase ω-3:ω-6 PUFA ratio; however, appropriate dose of FO to treat IFALD is unknown. METHODS After approval of exclusive FO ILE in the US for pediatric patients, we noted 2 adult patients with ongoing IFALD despite transition to mixed-oil (MO) ILE. They were transitioned to off-label FO ILE after review of literature regarding use of FO ILE in adult HPN patients was conducted to guide management. RESULTS The first case involves a 40-year-old female receiving HPN with IFALD refractory to MO ILE. MO ILE (with 15% FO) was provided at 50 g/d for 3 d/wk and combined with FO ILE at 50 g/d for 4 d/wk. This combination resulted in improvement in liver studies and allowed for decrease in dextrose calories. The second case involves a 49-year-old male receiving HPN (secondary to complications of necrotizing pancreatitis) who developed IFALD. FO ILE was used as the sole source of lipids and led to improvement in liver function tests. No evidence of essential fatty acid deficiency was found in either case. CONCLUSIONS Current case presentations and review of literature support the use of FO ILE to increase ω-3 PUFAs in patients with IFALD refractory to MO ILE. Additional research is necessary to delineate the dose of FO ILE necessary to achieve benefit.
Collapse
Affiliation(s)
- Manpreet S Mundi
- Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota, USA
| | - Sara L Bonnes
- Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
| | - Bradley R Salonen
- Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
| | - M Molly McMahon
- Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota, USA
| | - Robert Martindale
- Division of Gastrointestinal and General Surgery, Oregon Health Science University, Portland, Oregon, USA
| | - Ryan T Hurt
- Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota, USA.,Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.,Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA
| |
Collapse
|
3
|
Baker MA, Cho BS, Anez-Bustillos L, Dao DT, Pan A, O'Loughlin AA, Lans ZM, Mitchell PD, Nosé V, Gura KM, Puder M, Fell GL. Fish oil-based injectable lipid emulsions containing medium-chain triglycerides or added α-tocopherol offer anti-inflammatory benefits in a murine model of parenteral nutrition-induced liver injury. Am J Clin Nutr 2019; 109:1038-1050. [PMID: 30882140 PMCID: PMC6462433 DOI: 10.1093/ajcn/nqy370] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2018] [Accepted: 12/05/2018] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Fish oil (FO) intravenous lipid emulsions (ILEs) are used as a monotherapy to treat parenteral nutrition (PN)-associated liver disease and provide essential fatty acids (EFAs) needed to sustain growth and prevent EFA deficiency (EFAD). Studies have suggested that medium-chain triglycerides (MCTs) and α-tocopherol have anti-inflammatory properties. OBJECTIVE The purpose of this study was to test whether FO-ILEs containing MCTs and/or additional α-tocopherol decrease the inflammatory response to an endotoxin challenge compared with FO-ILE alone and preserve the ability to prevent PN-induced liver injury in mice. METHODS A murine model of PN-induced hepatosteatosis was used to compare the effects of ILEs formulated in the laboratory containing varying ratios of FO and MCTs, and subsequently FO- and 50:50 FO:MCT-ILE plus 500 mg/L α-tocopherol (FO + AT and 50:50 + AT, respectively). C57BL/6 mice receiving unpurified diet (UPD), PN-equivalent diet (PN) + saline, and PN + soybean oil (SO)-ILE served as controls. After 19 d, mice received an intraperitoneal saline or endotoxin challenge 4 h before being killed. Serum and livers were harvested for histologic analysis, fatty acid profiling, and measurement of systemic inflammatory markers (tumor necrosis factor-α, interleukin-6). RESULTS All ILEs were well tolerated and prevented biochemical EFAD. Livers of mice that received saline and SO developed steatosis. Mice that received 30:70 FO:MCT developed mild hepatosteatosis. All other FO-containing ILEs preserved normal hepatic architecture. Mice that received FO- or SO-ILE had significantly elevated systemic inflammatory markers after endotoxin challenge compared with UPD-fed controls, whereas 50:50 FO:MCT, 30:70 FO:MCT, FO + AT, and 50:50 + AT groups had significantly lower inflammatory markers similar to those seen in UPD-fed controls. CONCLUSIONS Mixed FO/MCT and the addition of α-tocopherol to FO improved the inflammatory response to endotoxin challenge compared with FO-ILE alone while still preventing PN-induced liver injury and EFAD in mice. There was no synergistic relation between α-tocopherol and MCTs.
Collapse
Affiliation(s)
| | - Bennet S Cho
- Vascular Biology Program and Department of Surgery
| | | | - Duy T Dao
- Vascular Biology Program and Department of Surgery
| | - Amy Pan
- Vascular Biology Program and Department of Surgery
| | | | | | - Paul D Mitchell
- Institutional Centers for Clinical and Translational Research
| | - Vania Nosé
- Department of Pathology, Massachusetts General Hospital, Boston, MA
| | - Kathleen M Gura
- Department of Pharmacy, Boston Children's Hospital, Boston, MA
| | - Mark Puder
- Vascular Biology Program and Department of Surgery
- Address correspondence to MP (e-mail: )
| | | |
Collapse
|
4
|
Bowzer J, Jackson C, Trushenski J. Hybrid striped bass feeds based on fish oil, beef tallow, and eicosapentaenoic acid/docosahexaenoic acid supplements: Insight regarding fish oil sparing and demand for n–3 long-chain polyunsaturated fatty acids1. J Anim Sci 2016; 94:978-88. [DOI: 10.2527/jas.2015-9199] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
|
5
|
Carlson SJ, Nandivada P, Chang MI, Mitchell PD, O'Loughlin A, Cowan E, Gura KM, Nose V, Bistrian BR, Puder M. The addition of medium-chain triglycerides to a purified fish oil-based diet alters inflammatory profiles in mice. Metabolism 2015; 64:274-82. [PMID: 25458829 PMCID: PMC4277814 DOI: 10.1016/j.metabol.2014.10.005] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/02/2014] [Revised: 09/29/2014] [Accepted: 10/06/2014] [Indexed: 12/17/2022]
Abstract
OBJECTIVE Parenteral nutrition associated liver disease (PNALD) is a deadly complication of long term parenteral nutrition (PN) use in infants. Fish oil-based lipid emulsion has been shown in recent years to effectively treat PNALD. Alternative fat sources free of essential fatty acids have recently been investigated for health benefits related to decreased inflammatory response. We hypothesized that the addition of medium-chain triglycerides (MCT) to a purified fish oil-based diet would decrease the response to inflammatory challenge in mice, while allowing for sufficient growth and development. MATERIALS/METHODS Six groups of ten adult male C57/Bl6 mice were pair-fed different dietary treatments for a period of twelve weeks, varying only in fat source (percent calories by weight): 10.84% soybean oil (SOY), 10% coconut oil (HCO), 10% medium-chain triglycerides (MCT), 3% purified fish oil (PFO), 3% purified fish oil with 3% medium-chain triglycerides (50:50 MCT:PFO) and 3% purified fish oil with 7.59% medium-chain triglycerides (70:30 MCT:PFO). An endotoxin challenge was administered to half of the animals in each group at the completion of dietary treatment. RESULTS All groups demonstrated normal growth throughout the study period. Groups fed MCT and HCO diets demonstrated biochemical essential fatty acid deficiency and decreased IL-6 and TNF-α response to endotoxin challenge. Groups containing PFO had increased inflammatory response to endotoxin challenge, and the addition of MCT to PFO mitigated this inflammatory response. CONCLUSION These results suggest that the addition of MCT to PFO formulations may decrease the host response to inflammatory challenge, which may pose potential for optimized PN formulations. Inclusion of MCT in lipid emulsions given with PN formulations may be of use in therapeutic interventions for disease states resulting from chronic inflammation.
Collapse
MESH Headings
- Animals
- Anti-Inflammatory Agents, Non-Steroidal/adverse effects
- Anti-Inflammatory Agents, Non-Steroidal/chemistry
- Anti-Inflammatory Agents, Non-Steroidal/therapeutic use
- Deficiency Diseases/etiology
- Deficiency Diseases/prevention & control
- Dietary Fats, Unsaturated/administration & dosage
- Dietary Fats, Unsaturated/adverse effects
- Dietary Fats, Unsaturated/therapeutic use
- Dietary Supplements/adverse effects
- Disease Models, Animal
- Emulsions
- Fatty Acids, Essential/adverse effects
- Fatty Acids, Essential/deficiency
- Fatty Acids, Essential/therapeutic use
- Fish Oils/adverse effects
- Fish Oils/chemistry
- Fish Oils/therapeutic use
- Lipopolysaccharides
- Liver/immunology
- Liver/metabolism
- Liver/pathology
- Male
- Mice, Inbred C57BL
- Non-alcoholic Fatty Liver Disease/etiology
- Non-alcoholic Fatty Liver Disease/metabolism
- Non-alcoholic Fatty Liver Disease/pathology
- Non-alcoholic Fatty Liver Disease/prevention & control
- Parenteral Nutrition, Total/adverse effects
- Triglycerides/administration & dosage
- Triglycerides/adverse effects
- Triglycerides/chemistry
- Triglycerides/therapeutic use
- Weight Gain
Collapse
Affiliation(s)
- Sarah J Carlson
- Boston Children's Hospital Department of Surgery and the Vascular Biology Program, Boston MA
| | - Prathima Nandivada
- Boston Children's Hospital Department of Surgery and the Vascular Biology Program, Boston MA
| | - Melissa I Chang
- Boston Children's Hospital Department of Surgery and the Vascular Biology Program, Boston MA
| | - Paul D Mitchell
- Boston Children's Hospital Clinical Research Center, Boston MA
| | - Alison O'Loughlin
- Boston Children's Hospital Department of Surgery and the Vascular Biology Program, Boston MA
| | - Eileen Cowan
- Boston Children's Hospital Department of Surgery and the Vascular Biology Program, Boston MA
| | - Kathleen M Gura
- Boston Children's Hospital Department of Pharmacy, Boston MA
| | - Vania Nose
- Massachusetts General Hospital Department of Pathology, Boston MA
| | - Bruce R Bistrian
- Beth Israel Deaconess Medical Center Department of Medicine, Boston MA
| | - Mark Puder
- Boston Children's Hospital Department of Surgery and the Vascular Biology Program, Boston MA.
| |
Collapse
|
6
|
Nandivada P, Carlson SJ, Cowan E, Chang MI, Gura KM, Puder M. Role of parenteral lipid emulsions in the preterm infant. Early Hum Dev 2013; 89 Suppl 2:S45-9. [PMID: 23998451 DOI: 10.1016/j.earlhumdev.2013.08.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Parenteral nutrition (PN) is necessary for infants unable to receive adequate calories enterally due to prematurity, decreased bowel length, or functional intestinal disorders. While PN can be life saving, its use is associated with significant risks of sepsis from catheter-associated infections and progressive liver dysfunction from prolonged use. The preterm infant population is at highest risk for these complications due to the presence of multiple comorbidities and immaturity of the biliary system. Strong data has implicated parenteral lipids in the multifactorial pathogenesis of PN-associated liver disease (PNALD). However, lipids are essential in early infant development, particularly in the neurocognitive development of preterm infants. Substitution of the lipid source from soybean oil to fish oil has emerged as a safe and efficacious treatment of PNALD, with marked improvements in morbidity and mortality. Knowledge of the developmental needs and physiologic limitations of preterm infants is crucial to optimizing parenteral lipid administration to nurture growth, and minimize and treat associated complications. The purpose of this review is to provide an overview of lipid requirements of the preterm infant and discuss the role of parenteral lipid emulsions in the management of PNALD and other diseases of prematurity.
Collapse
Affiliation(s)
- Prathima Nandivada
- Boston Children's Hospital, Department of Surgery and Vascular Biology Program, 300 Longwood Avenue, Fegan 3, Boston, MA, USA
| | | | | | | | | | | |
Collapse
|
7
|
Le HD, Fallon EM, Kalish BT, de Meijer VE, Meisel JA, Gura KM, Nose V, Pan AH, Bistrian BR, Puder M. The effect of varying ratios of docosahexaenoic acid and arachidonic acid in the prevention and reversal of biochemical essential fatty acid deficiency in a murine model. Metabolism 2013; 62:499-508. [PMID: 23151438 PMCID: PMC3608741 DOI: 10.1016/j.metabol.2012.10.003] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/13/2012] [Revised: 08/31/2012] [Accepted: 10/09/2012] [Indexed: 01/24/2023]
Abstract
OBJECTIVE Essential fatty acids (EFA) are necessary for growth, development, and biological function, and must be acquired through the diet. While linoleic acid (LA) and alpha-linolenic acid (ALA) have been considered the true EFAs, we previously demonstrated that docosahexaenoic acid (DHA) and arachidonic acid (AA) taken together as the sole source of dietary fatty acids can prevent biochemical essential fatty acid deficiency (EFAD). This study evaluates the effect of varying dietary ratios of DHA:AA in the prevention and reversal of biochemical EFAD in a murine model. METHODS Using a murine model of EFAD, we provided mice with 2.1% of daily caloric intake in varying DHA:AA ratios (1:1, 5:1, 10:1, 20:1, 200:1, 100:0) for 19 days in association with a liquid high-carbohydrate fat-free diet to evaluate the effect on fatty acid profiles. In a second experiment, we evaluated the provision of varying DHA:AA ratios (20:1, 200:1, 100:0) on the reversal of biochemical EFAD. RESULTS Mice provided with DHA and AA had no evidence of biochemical EFAD, regardless of the ratio (1:1, 5:1, 10:1, 20:1, 200:1, 100:0) administered. Biochemical EFAD was reversed with DHA:AA ratios of 20:1, 200:1, and 100:0 following 3 and 5 weeks of dietary provision, although the 20:1 ratio was most effective in the reversal and stabilization of the triene:tetraene ratio. CONCLUSION Provision of DHA and AA, at 2.1% of daily caloric intake in varying ratios can prevent biochemical evidence of EFAD and hepatic steatosis over the short-term, with a ratio of 20:1 DHA:AA most effectively reversing EFAD.
Collapse
Affiliation(s)
- Hau D. Le
- Department of Surgery and the Vascular Biology Program, Boston Children’s Hospital and Harvard Medical School
| | - Erica M. Fallon
- Department of Surgery and the Vascular Biology Program, Boston Children’s Hospital and Harvard Medical School
| | - Brian T. Kalish
- Department of Surgery and the Vascular Biology Program, Boston Children’s Hospital and Harvard Medical School
| | - Vincent E. de Meijer
- Department of Surgery and the Vascular Biology Program, Boston Children’s Hospital and Harvard Medical School
| | - Jonathan A. Meisel
- Department of Surgery and the Vascular Biology Program, Boston Children’s Hospital and Harvard Medical School
| | | | - Vania Nose
- Department of Pathology, University of Miami and Miller School of Medicine, Miami, FL
| | - Amy H. Pan
- Department of Surgery and the Vascular Biology Program, Boston Children’s Hospital and Harvard Medical School
| | - Bruce R. Bistrian
- Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA
| | - Mark Puder
- Department of Surgery and the Vascular Biology Program, Boston Children’s Hospital and Harvard Medical School
- Corresponding author: Mark Puder, MD, PhD, 300 Longwood Ave, Fegan 3; Boston, MA 02115, Phone: 617-355-1838, Fax: 617-730-0477;
| |
Collapse
|